Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Daniel Fresán
Observed names:
D Fresan,
DANIEL FRESÁN
Institution:
European Society of Clinical Microbiology and Infectious Diseases
Observed institutions:
Complejo Hospitalario de Navarra,
European Society of Clinical Microbiology and Infectious Diseases
ORCID:
0000-0002-4647-1823
Observed ORCID:
0000-0002-4647-1823
OpenAlex ID:
A5016277458
Real-world experience of therapeutic drug monitoring and PK/PD achievement of ceftaroline administered by different infusion regimens in patients with confirmed infections caused by Gram-positive bacteria
2023
·
Daniel Fresán
, Sonia Luque
, et al.
·
Journal of Antimicrobial Chemotherapy
·
7
PDF
Pharmacokinetics/pharmacodynamics and therapeutic drug monitoring of ceftazidime/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infections—authors’ response
2023
·
Daniel Fresán
, Sonia Luque
, et al.
·
Journal of Antimicrobial Chemotherapy
·
5
Pharmacokinetics of aztreonam/avibactam in a critically ill patient with a class B metallo-β-lactamase producing Enterobacteriaceae and receiving continuous renal replacement therapy
2025
·
Daniel Fresán
, Maria Pilar Gracia-Arnillas
, et al.
·
Journal of Antimicrobial Chemotherapy
·
4
An easy-to-use predictive score for identifying patients at risk of suboptimal linezolid exposure and candidates for therapeutic drug monitoring
2025
·
Daniel Fresán
, Luisa Sorlí
, et al.
·
International Journal of Antimicrobial Agents
·
3
4CPS-031 Therapeutic drug monitoring of ceftazidime/avibactam administered by continuous infusion: PK/PD target achievement and clinical outcomes
2023
·
D Fresan
, S Luque
, et al.
·
European Journal of Hospital Pharmacy
·
1
PDF
Early adequate linezolid concentrations and clinical outcomes in confirmed Gram-positive infections: the role of therapeutic drug monitoring
2026
·
Daniel Fresán
, Luisa Sorlí
, et al.
·
Journal of Antimicrobial Chemotherapy
Aztreonam-avibactam frente a Enterobacterias productoras de carbapenemasas: eficacia clínica, microbiológica y monitorización terapéutica en vida real
2026
·
SONIA LUQUE
, JOAN TORRA-GARCIA
, et al.
·
Sociedad Española de Farmacia Hospitalaria eBooks
4CPS-002 Effectiveness and safety of monoclonal antibodies for migraine prevention after two and a half years of clinical experience
2023
·
D Fresan
, A Yerro
, et al.
·
European Journal of Hospital Pharmacy
PDF
5PSQ-012 Are 12 months of treatment with monoclonal antibodies sufficient for migraine attack prevention?
2022
·
D Fresan
, E Lacalle
, et al.
·
European Journal of Hospital Pharmacy
PDF
4CPS-218 Evaluation of the impact of incorporating a pharmacist into a hospital emergency department
2022
·
D Fresan
, I Ortega
, et al.
·
European Journal of Hospital Pharmacy
PDF
Show more works
View as search
Works count:
10
Citation count:
20
H-index:
3
I10-index:
Year
Topic
Type